Similar to anthracyclines, curaxins have demonstrated anti-tumor activity in multiple preclinical models (i.e. have higher toxicity to tumor cells than normal cells), suggesting that tumor cells are more sensitive to ChrD than normal cells (6–7,9,12–15). The gene discussed is CHRD; the disease is neoplasm.